Latest Biotech News

Function Health raised $298 million in a Series B round led by Redpoint Ventures, propelling the lab‑testing startup to a $2.5 billion valuation. The Austin‑based company provides consumer and...

Profluent closed a $106 million financing led by Altimeter Capital and Bezos Expeditions to expand AI‑driven protein design capabilities. The Emeryville company said it will deploy the capital to...

Aspen Neuroscience secured $115 million in Series C financing to support its personalized autologous cell therapy program for Parkinson’s disease and to expand manufacturing capacity. The funding...

GSK signed early‑stage discovery agreements with Flagship Pioneering portfolio companies Profound Therapeutics and Quotient Therapeutics, validating proteomic and somatic‑genomics platforms for...

Researchers from David Liu’s group at the Broad Institute published a new prime editing‑based strategy, PERT (prime editing‑installed suppressor tRNAs), that converts endogenous tRNAs into...

Tessera Therapeutics confirmed it will start the first human trial of its in vivo gene‑writing platform next month, targeting an adult population with a rare genetic disorder. The move marks the...

Abbott announced a definitive agreement to acquire Exact Sciences for $105 per share, valuing the cancer-diagnostics company at roughly $21 billion. The acquisition brings Cologuard, Oncotype DX,...

The U.S. Food and Drug Administration granted accelerated approval to Bayer’s oral HER2-directed therapy Hyrnuo (sevabertinib) for adults with advanced non–small-cell lung cancer harboring...

The Centers for Disease Control and Prevention revised a vaccine-safety webpage to state that a causal link between vaccines and autism cannot be entirely ruled out — a marked change from the...

Function Health closed a $298 million Series B round that values the lab-testing startup at $2.5 billion and underscores investor demand for consumer-facing diagnostics platforms. The Austin-based...

Moderna secured $1.5 billion in financing to support its strategic pivot toward seasonal vaccines, oncology and rare disease programs and to help drive the company to breakeven in coming years....

Hepta, founded by former Grail scientists, released proof-of-concept data showing that cfDNA methylation patterns reflect liver disease biology, including fibrosis, and correlate with single-cell...

Tel Aviv startup Cassidy Bio closed an $8 million seed round led by Ahren Innovation Capital to develop an AI platform that predicts optimal combinations of guide RNAs, editing enzymes and...

Profluent closed a $106 million financing led by Altimeter Capital and Bezos Expeditions to advance large-scale AI models for protein design across therapeutics, agriculture and biomanufacturing....

Tessera Therapeutics confirmed it will start its first-in-human study of an in vivo gene writing platform next month, testing the approach in adults with a rare genetic disease. The company said...

Researchers in David Liu’s laboratory reported a prime-editing strategy called PERT (prime editing–installed suppressor tRNAs) that converts an endogenous tRNA into a suppressor RNA to read...

Abbott announced an agreement to acquire Exact Sciences for an enterprise value of roughly $23 billion, paying $105 per share in cash and folding Exact into Abbott’s diagnostics business. The...

GSK signed feasibility agreements with two Flagship Pioneering platform companies—ProFound Therapeutics and Quotient Therapeutics—to mine proteomic and somatic genomic datasets for drug targets in...

Tessera Therapeutics confirmed it will initiate its first-in-human trial next month to test its in vivo gene-writing platform in adults with a rare genetic disease. The move transitions Tessera...

Two academic teams published complementary advances aimed at broadening prime editing’s therapeutic reach. David Liu’s Broad Institute group reported a strategy (PERT) that uses prime editing to...